Pharming Group (NASDAQ:PHAR) Hits New 1-Year High – Still a Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $18.20 and last traded at $18.1050, with a volume of 1567 shares trading hands. The stock had previously closed at $18.09.

Analyst Upgrades and Downgrades

PHAR has been the subject of a number of recent research reports. Zacks Research raised Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 22nd. Finally, Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research note on Saturday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $38.00.

Pharming Group Trading Down 1.6%

The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. The firm’s fifty day moving average is $15.96 and its two-hundred day moving average is $13.73. The firm has a market cap of $1.22 billion and a P/E ratio of -1,778.22.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, November 6th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.05 by $0.05. The firm had revenue of $97.30 million during the quarter, compared to analysts’ expectations of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. Analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 52,147 shares of the company’s stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.